SPA
RLAY icon

Sherbrooke Park Advisers’s Relay Therapeutics RLAY Stock Holding History

Sherbrooke Park Advisers’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,519
Closed -$53.8K – 740
2025
Q1 		$53.8K Sell
20,519
-8,440
-29% -$33.1K 0.03% 547
2024
Q4 		$119K Sell
28,959
-10,532
-27% -$57.3K 0.04% 646
2024
Q3 		$280K Buy
39,491
+24,526
+164% +$183K 0.06% 598
2024
Q2 		$97.6K Sell
14,965
-29,727
-67% -$203K 0.02% 840
2024
Q1 		$371K Buy
+44,692
New +$436K 0.07% 479

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sherbrooke Park Advisers's RLAY Position: Q2 2025 in Review

Sherbrooke Park Advisers sold out of Relay Therapeutics (RLAY) in Q2 2025, closing a stake of 20,519 shares — an estimated $53.8K sold.

Sherbrooke Park Advisers first reported a position in RLAY in Q1 2024 and held it in 5 quarters. The position peaked at $371K in Q1 2024. 208 funds tracked by Wall St. Rank hold RLAY as of Q2 2025.

  • Sherbrooke Park Advisers reported no remaining Relay Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 20,519 Relay Therapeutics shares in Q2 2025, an estimated $53.8K.
  • Sherbrooke Park Advisers first reported a position in Relay Therapeutics in Q1 2024 and held it in 5 quarters.
  • Sherbrooke Park Advisers's Relay Therapeutics position peaked at $371K in Q1 2024.
  • 208 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.